Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: AQP4+ NMOSD Clear all
Recruiting No phase listed Observational
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced May 21, 2026, 7:40 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Neuromyelitis Optica, NMO Spectrum Disorder
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced May 21, 2026, 7:40 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Eculizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
19
States / cities
Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced May 21, 2026, 7:40 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Bevacizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced May 21, 2026, 7:40 PM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
Ravulizumab
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced May 21, 2026, 7:40 PM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
AQP4+ NMOSD
Interventions
CC-97540 (BMS-986353), Fludarabine, Cyclophosphamide, Tocilizumab
Biological · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced May 21, 2026, 7:40 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder, NMOSD
Interventions
Satralizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 11 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 21, 2026, 7:40 PM EDT